Vischer advised Oculis SA on the deal, while Walder Wyss advised Hyfinity Investments. Oculis S.A., a late-stage biopharmaceutical company focused on developing transformative ophthalmic treatments to…
This content is for Standard 1 Year members only. LoginJoin Now
Author: Federica Tiefenthaler
…
This content is for Standard 1 Year members only. LoginJoin Now